Literature DB >> 11086200

Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.

Y Hosomi1, T Yokose, Y Hirose, R Nakajima, K Nagai, Y Nishiwaki, A Ochiai.   

Abstract

A low incidence of lung carcinoma has been reported in cases of prolonged use of aspirin. Cyclooxygenase (COX) 2 expression is frequently seen in adenocarcinoma of the lung, but COX-2 expression in atypical adenomatous hyperplasia (AAH), a possible precursor lesion of adenocarcinoma of the lung, is not known. COX-2 expression was immunohistochemically evaluated in a cohort of 20 cuboidal cell hyperplasias (CCH), 81 atypical adenomatous hyperplasias (AAH), 18 bronchioloalveolar carcinomas (BAC), and 88 invasive adenocarcinomas (I-Ad). The relationship between COX-2 expression and clinicopathologic factors and survival was examined. COX-2 overexpression was detected in over 80% of CCH, AAH, BAC, and I-Ad. However, overexpression was diffuse in AAH (71.6%) and BAC (66.7%). No relationship was found between COX-2 expression and clinicopathological factors or survival. COX-2 expression was most frequently detected in AAH. These findings, taken with previous reports that treatment with COX-2 inhibitor suppresses human colon carcinogenesis, suggest that inhibition of COX-2 may reduce the incidence of human adenocarcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086200     DOI: 10.1016/s0169-5002(00)00132-x

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  48 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

3.  Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.

Authors:  M Dohadwala; J Luo; L Zhu; Y Lin; G J Dougherty; S Sharma; M Huang; M Pold; R K Batra; S M Dubinett
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

4.  2-Ethoxybenzamide stimulates melanin synthesis in B16F1 melanoma cells via the CREB signaling pathway.

Authors:  Kazuomi Sato; Ryosuke Ando; Honoka Kobayashi; Takashi Nishio
Journal:  Mol Cell Biochem       Date:  2016-09-16       Impact factor: 3.396

5.  COX-2 inhibitors in NSCLC: never-ending story or misplaced?

Authors:  Alex Martinez-Marti; Alejandro Navarro; Enriqueta Felip
Journal:  Transl Lung Cancer Res       Date:  2018-09

Review 6.  Lung cancer. 1: prevention of lung cancer.

Authors:  G E Goodman
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

7.  Expression of cyclooxygenase (COX)-2 as a prognostic factor in nasopharyngeal cancer.

Authors:  Kyubo Kim; Hong-Gyun Wu; Suk Won Park; Chong Jai Kim; Charn Il Park
Journal:  Cancer Res Treat       Date:  2004-06-30       Impact factor: 4.679

8.  PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells.

Authors:  Chen Chen; Dinghua Yang; Qinghua Zeng; Liang Luo; Chengzhi Cai
Journal:  Exp Ther Med       Date:  2018-03-20       Impact factor: 2.447

9.  Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study.

Authors:  Christopher G Slatore; David H Au; Alyson J Littman; Jessie A Satia; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

10.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.